Seyed Ali Jalalifar

Mr. Seyed Ali Jalalifar

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 January 2023 in IEEE Journal of Biomedical and Health Informatics
Verified
Journal Article
Open access
SJSeyed Ali Jalalifar
Seyed Ali Jalalifar
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
ASAli Sadeghi-Naini
Ali Sadeghi-Naini
The standard clinical approach to assess the radiotherapy outcome in brain metastasis is through monitoring the changes in tumour size on longitudinal MRI. This assessment requires contouring the tumour on many volumetric images acquired before and at several follow-up scans after the treatment that is routinely done manually by oncologists with a substantial burden on the clinical workflow. In this work, we introduce a novel system for automatic assessment of stereotactic radiation therapy (SRT) outcome in brain metastasis using standard serial MRI. At the heart of the proposed system is a deep learning-based segmentation framework to delineate tumours longitudinally on serial MRI with high precision. Longitudinal changes in tumour size are then analyzed automatically to assess the local response and detect possible adverse radiation effects (ARE) after SRT. The system was trained and optimized using the data acquired from 96 patients (130 tumours) and evaluated on an independent test set of 20 patients (22 tumours; 95 MRI scans). The comparison between automatic therapy outcome evaluation and manual assessments by expert oncologists demonstrates a good agreement with an accuracy, sensitivity, and specificity of 91%, 89%, and 92%, respectively, in detecting local control/failure and 91%, 100%, and 89% in detecting ARE on the independent test set. This study is a step forward towards automatic monitoring and evaluation of radiotherapy outcome in brain tumours that can streamline the radio-oncology workflow substantially.

20 October 2022 in Cancers
Verified
Journal Article
Open access
PDF file
SJSeyed Ali Jalalifar
Seyed Ali Jalalifar
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
ASAli Sadeghi-Naini
Ali Sadeghi-Naini
Significantly affecting patients’ clinical course and quality of life, a growing number of cancer cases are diagnosed with brain metastasis (BM) annually. Stereotactic radiotherapy is now a major treatment option for patients with BM. However, it may take months before the local response of BM to stereotactic radiation treatment is apparent on standard follow-up imaging. While machine learning in conjunction with radiomics has shown great promise in predicting the local response of BM before or early after radiotherapy, further development and widespread application of such techniques has been hindered by their dependency on manual tumour delineation. In this study, we explored the impact of using less-accurate automatically generated segmentation masks on the efficacy of radiomic features for radiotherapy outcome prediction in BM. The findings of this study demonstrate that while the effect of tumour delineation accuracy is substantial for segmentation models with lower dice scores (dice score ≤ 0.85), radiomic features and prediction models are rather resilient to imperfections in the produced tumour masks. Specifically, the selected radiomic features (six shared features out of seven) and performance of the prediction model (accuracy of 80% versus 80%, AUC of 0.81 versus 0.78) were fairly similar for the ground-truth and automatically generated segmentation masks, with dice scores close to 0.90. The positive outcome of this work paves the way for adopting high-throughput automatically generated tumour masks for discovering diagnostic and prognostic imaging biomarkers in BM without sacrificing accuracy.

28 May 2021
Verified
Book Chapter
Closed access
PDF file
SJSeyed Ali Jalalifar
Seyed Ali Jalalifar
HSHany Soliman
Hany Soliman
ASArjun Sahgal
Arjun Sahgal
ASAli Sadeghi-Naini
Ali Sadeghi-Naini
<!----> <!----> Brain metastases are the most common malignancy of the central nervous system, occurring in about 10% to 30% of all cancer patients [1]. The incidence of brain metastasis is increasing because of the improvement in control of systemic disease, better radiologic detection, and prolonged survival of cancer patients [2]. The estimated incidence of new brain metastases in the United States is between 7 and 14 per 100,000 persons based on population studies. The prevalence of metastases to the brain is expected to continue to increase in the future [2]. Autopsy and clinical data reveal that over 100,000 patients develop brain metastases annually in the United States [2]. <!----> <!---->